Spadin analog · TREK-1 blocker candidate
PE-22-28
Cited range Depression-model peptide
What it is
PE-22-28 is a shortened analog in the spadin family, studied as a TREK-1 blocker in depression and neurogenesis models.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- A short spadin-related peptide studied for antidepressant-like and neurogenesis effects in animals.
- Mood-research bin, not a GH or fat-loss peptide.
- Early days.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Blocking TREK-1 is hypothesized to raise neuronal excitability in mood circuits in some animal assays. That is still preclinical framing.
Possible side effects / caveats
Almost no human safety file. Mood-circuit excitability can cut toward agitation or sleep change in theory.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Cited research talk | Low-mcg IN or SC figures | Daily in secondary sources | Unstandardized |